Class A Medical Devices in Singapore: Product Notification

1. Key takeaways

Class A devices are exempt from product registration, but not from compliance obligations. Under GN-15 R15 Section 3.1, Class A devices are not subject to product registration; instead, their manufacturers and importers must submit a Product Notification through SHARE, placing the product into HSA’s Class A medical device database. At the same time, any entity dealing in the product must still hold a valid Dealer’s Licence, and post-market obligations such as adverse event reporting continue to apply. In other words, the exemption removes one procedural step — registration — but leaves the entire compliance architecture intact, and companies that treat Class A as a deregulated category run into problems precisely because they underestimated what remains.

• Class A devices require product notification via SHARE before supply, not registration.
• Notification does not remove the need for a Dealer’s Licence matched to the entity’s actual activities.
• Companies dealing only in Class A devices may substitute a Declaration of Conformity to a QMS for ISO 13485 / MDSAP / GDPMDS certificates under GN-02 R8.
• Adverse event reporting duties apply to Class A products just as they do to higher-risk classes.

2. Legal basis

The framework for Class A devices combines the registration guidance that grants the exemption, the dealer guidance specific to Class A, the licensing guidance, and the statutory Parts of the Health Products Act from which the obligations derive.

Read together, these instruments make clear that the Class A exemption is a substitution of procedure, not a removal of oversight. The product must still be visible to HSA through the notification database, the entity must still be licensed, and the post-market system must still function. Each element is verifiable by the authority independently of the others, which is why a gap in any one of them surfaces during customs checks or enforcement reviews.

3. Expert insights

Insight 1: The phrase “registration-exempt” is systematically misread. Among the clients we work with, more than half interpret “Class A is registration-exempt” as meaning that Class A requires nothing at all. In reality, three things must be done for Class A in Singapore: (1) product notification; (2) the Dealer’s Licence; (3) post-market vigilance. If any one of the three is missing, problems can arise at the customs or HSA enforcement stage. The misreading is understandable — the word exemption invites it — but the operational consequences are real, because a product that reaches the market without notification has no lawful basis for supply, and an entity that supplies without a licence commits an offence regardless of the risk class of the product involved.

Insight 2: Companies dealing only in Class A devices have a dedicated, lighter QMS evidence channel. This is the most valuable but least publicised rule for Class A. Under GN-02 R8, if a company deals only in Class A medical devices, it may submit a Declaration of Conformity to a quality management system in place of ISO 13485 / MDSAP / GDPMDS certificates. For Chinese manufacturers whose product lines concentrate on low-risk consumables, this channel saves both certification cost and time. The saving is not trivial: certification projects consume budget and calendar months, and the declaration route removes that dependency for pure Class A operators while still evidencing that a functioning quality system exists behind the products.

Insight 3: Product notification must precede supply. Notification is not a retrospective filing to be completed after the fact. According to HSA’s position, Class A devices should be notified before they are supplied, so that the product enters HSA’s Class A database in advance. That database is the authority’s reference for judging whether a product has been lawfully notified, and it is the first item we check in every compliance health review. If a product is already in the field and absent from the database, remediation becomes urgent, because every day of continued supply deepens the exposure rather than reducing it.

Insight 4: Class A carries vigilance obligations; low risk does not mean exempt. HSA’s adverse event reporting obligation applies to “all companies dealing in medical devices including importers, manufacturers, suppliers and registrants” — Class A is not carved out. Low risk does not mean zero risk, and it certainly does not mean zero obligation. The AE reporting machinery, including the internal awareness processes that feed it, must therefore be established for Class A product lines with the same seriousness as for registered products, even though the likelihood of reportable events is lower.

4. Practical recommendations

• Bring Class A product lines into the compliance ledger: establish a three-column ledger covering notification status, dealer licence coverage and the designated vigilance owner; do not relax oversight simply because the product is registration-exempt.
• Map the licence combination first: import only, or import plus wholesale? The corresponding licences differ (see Chapters 31 and 32 for detail).
• Use the QMS relief channel fully: where the business is genuinely pure Class A, assess the feasibility of substituting a declaration of conformity for system certification; but once Class B or above is involved, the channel no longer applies.
• Re-plan when expanding into Class B: moving up a class changes the QMS requirements, the registration pathway and the fee structure all at once, and must be planned in advance.

5. Verification checklist

• □ The product classification has been confirmed as Class A
• □ The product notification has been submitted via SHARE and the product appears in HSA’s Class A database
• □ The dealing entity holds a Dealer’s Licence matching its actual activities
• □ Applicability of the QMS declaration-of-conformity channel has been confirmed (where dealing only in Class A)
• □ A vigilance owner has been designated and brought into the AE reporting process
• □ Notification status is tracked in the compliance ledger and reviewed periodically

Regulatory information verified as of: 26 October 2026

Source level: Tier 2 (GN-15 R15 Section 3.1, GN-22 R8, GN-02 R8, HSA adverse event reporting page)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com